Enapotamab vedotin

Product Specifications

CAS Number

1912424-97-5

Target

Antibody-Drug Conjugates (ADCs) |||TAM Receptor

Related Pathways

Tyrosine Kinase/Adaptors|||Antibody-drug Conjugate/ADC Related

Purity

>95.0%

Bioactivity

Enapotamab vedotin is an investigational antibody-drug conjugate (ADC) specifically targeting the receptor tyrosine kinase AXL. it consists of a monoclonal antibody linked to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) and demonstrates significant inhibitory potential against high AXL-expressing non-small cell lung cancer (NSCLC), including tumors with resistance to EGFR inhibitors like Osimertinib.